Five Questions Concerning Managing Hepatitis C in the Justice System

• Autores: Anne C. Spaulding, Madeline G. Adee, Robert T. Lawrence, Jagpreet Chhatwa, William von Oehsen
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 32, Nº. 2, 2018 (Ejemplar dedicado a: Overcoming Barriers to Eliminate Hepatitis C), págs. 323-345
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing. While high prices for direct-acting antivirals discourage treatment, potential strategies exist to lower prices.